CMR Surgical raises more than £154m in debt and equity to expand commercial reach of its surgical robot
The financing round was backed by existing major investors and new participant Trinity Capital.
CMR Surgical develops the Versius Surgical Robotic System, a widely adopted soft tissue surgical robot used in tens of thousands of procedures worldwide. Headquartered in Cambridge, the company works to make robotic minimal access surgery more accessible.
CMR Surgical has secured more than £154m in a new debt and equity financing round backed by existing investors alongside new backer Trinity Capital. The company will direct the capital towards accelerating the global commercialisation of its Versius Surgical Robotic System, with a particular focus on entering the United States market. Funds will also support ongoing product development and clinical trials.
Versius ranks as the second most utilised soft tissue surgical robot globally, having completed over 30,000 procedures across more than 30 countries. The latest injection of capital follows expanding international adoption and clinical studies spanning pediatric surgery and transoral robotic procedures.
From the founder
"CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to give thanks to our CFO, Andre Nel, and the team for securing this financing to provide the foundation for realising our strategic vision of making robotic assisted surgery accessible to all patients who need it whilst accelerating future product development."
Massimiliano Colella
Chief Executive Officer at CMR Surgical
Investor perspective
"Trinity Capital is excited to partner with CMR Surgical at this important juncture. CMR has established itself as a trailblazer in surgical robotics, with Versius already proving its value to surgeons and patients worldwide. We are confident in CMR’s vision and leadership, and our investment reflects our belief that Versius will continue to drive a new era in minimally invasive surgery. We look forward to supporting CMR as it continues to scale and transform surgical care on a global level."
Rob Lake
Senior Managing Director, Life Sciences, Trinity Capital
Use of funds
- 01Expand into international markets
- 02Continue product development
- 03Fund research and development
Investors
Categories
About the company
CMR Surgical
CMR Surgical manufactures the Versius system for robotic minimal access surgery.